Evotec将以约3.5亿美元现金将Evotec Biologics图卢兹工厂出售给Sandoz AG

Evotec SE（法兰克福证券交易所：EVT，SDAX/TecDAX，Prime Standard，TRQX：EVTd（TRQX：EVTdFTRQX：EVTdrTRQX：EVTdaTRQX：EVTdnTRQX：EVTdkTRQX：EVTdfTRQX：EVTduTRQX：EVTdrTRQX：EVTdtTRQX：EVTd TRQX：EVTdSTRQX：EVTdtTRQX：EVTdoTRQX：EVTdcTRQX：EVTdkTRQX：EVTd TRQX：EVTdETRQX：EVTdxTRQX：EVTdcTRQX：EVTdhTRQX：EVTdaTRQX：EVTdnTRQX：EVTdgTRQX：EVTdeTRQX：EVtd：TRQX：EVTdETRQX：EVTdVTRQX：EVTdTTRQX：EVTdTTRQX：EVTdTRQX：EVTdTRQX：EVTdDTRQX：EVTdATRQX：EVTdXTRQX：EVtd/TRQX：EVTdTTRQX：EVTdeTRQX：EVTdcTRQX：EVTdDTRQX：EVTdATRQX：EVTdXTRQX：EVTdXTRQX：EVtd，TRQX：EVtd TRQX：EVTdPTRQX：EVTdrTRQX：EVTdiTRQX：EVTdmTRQX：EVTdeTRQX：EVTdTRQX：EVTdTRQX：EVTdTRQX：EVTdtTRQX：EVTdaTRQX：EVTdnTRQX：EVTddTRQX：EVTdaTRQX：EVTdrTRQX：EVTddTRQX：EVTdTRQX：EVTdITRQX：EVTdITRQX：EVTdStrQX：EVTdITRQX：EVTdNTRQX：EVtd：TRQX：EVtd TRQX：EVTdDTRQX：EVTdETRQX：EVTd0TRQX：EVTd0TRQX：EVTd0TRQX：EVTd5TRQX：EVTd6 TRQX：EVTD 6 TRQX：EVTD 4 TRQX：EVTD 8 TRQX：EVTD 0 TRQX：EVTD 9 TRQX：EVTD，TRQX：EVTD TRQX：EVTdTRQX：EVTdWTRQX：EVTdKTRQX：EVTdNTRQX：EVTD TRQX：EVTD 5 TRQX：EVTD 6 TRQX：EVTD 6 TRQX：EVTD 4 TRQX：EVTD 8 TRQX：EVTD 0 TRQX：EVTD; TRQX：EVtd TRQX：EVTdNTRQX：EVTdATRQX：EVTdSTRQX：EVTdDTRQX：EVTdATRQX：EVTdQTRQX：EVTdQTRQX：EVtd：TRQX：EVtd EVTdsTRQX：EVTdtTRQX：EVTdrTRQX：EVTdoTRQX：EVTdnTRQX：EVTdgTRQX：EVTD> TRQX：EVTdETRQX：EVTdVTRQX：EVTdOTRQX：EVtd EVtd/TRQX：EVTdsTRQX：EVTdtTRQX：EVTdrTRQX：EVTdoTRQX：EVTdnTRQX：EVTdgTRQX：EVtd> TRQX：EVtd）TRQX：EVtd，WKN 566480，NASDAQ：EVO）是一家引领药物发现和开发未来的生命科学公司，今天宣布成功签署将Just-Evotec Biologics图卢兹工厂出售给全球仿制药和生物仿制药领导者Sandoz AG（SIX：SDZ）（OTCQX：SDZNY）。

根据这项具有里程碑意义的交易，Sandoz将以约3.5亿美元现金收购Just-Evotec Biologics EU 100%的股份，以及Evotec连续制造平台技术的无限期技术许可。该协议包括额外的许可费和开发收入，包括基于成功的里程碑，未来几年总计超过3亿美元。未来，Evotec预计将受益于最多十种生物仿制药的技术和早期开发组合的特许权使用费，目标是超过900亿美元的净原创销售市场。